-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOCARDIA ANNOUNCES FIRST PATIENT IN PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND CARDIAMP HF II CLINICAL TRIAL OF THE COMPANY’S LEAD CELL THERAPY FOR TREATMENT OF HEART FAILURE

Reuters·05/01/2025 13:00:04

Please log in to view news